Guest guest Posted May 3, 2005 Report Share Posted May 3, 2005 For those of you who subscribe to the Asian CML list (http://asia./group/AsianCMLSupportGroup/) Roy has just written a nice summary (post #31610) of an in-vitro study of a combination of IM plus a new phosphoinositide-dependent kinase-1 inhibitor OSU-03012, showing efficacy against the T315I mutation, which I just referrred to in a previous post. I gather from Roy's post that they're working to accelerate the approval process for a clinical trial - first of OSU-03012, then of the combination. Thanks Roy - if you're listening. R Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.